-+ 0.00%
-+ 0.00%
-+ 0.00%
Fosun Pharma Says AR1001 Slows Alzheimer's Decline 31% in Phase 3 Monotherapy Population
Share
Listen to the news
Fosun Pharma Says AR1001 Slows Alzheimer's Decline 31% in Phase 3 Monotherapy Population
  • Fosun Pharma reported AriBio's oral AR1001 significantly slowed clinical decline in a prespecified monotherapy group in its Phase 3 Alzheimer's trial.
  • The monotherapy group comprised patients not receiving acetylcholinesterase inhibitors or memantine at baseline.
  • Results in the overall trial population favored AR1001 but did not reach statistical significance.
  • The POLARIS-AD results were presented at the 2026 Clinical Trials on Alzheimer Disease conference in Boston.
  • AR1001 was generally well tolerated over 52 weeks, with serious adverse events similar to placebo.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fosun International Limited published the original content used to generate this news brief on November 17, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending